Citigroup’s Elevation Oncology ELEV Stock Holding History

Citigroup’s Portfolio ELEV Stock Details ELEV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-13,442	Closed	-$4.93K	–	6154
2025 Q2	$4.93K	Sell	13,442 -66,526	-83%	-$22.2K	﹤0.01%	5283
2025 Q1	$20.7K	Buy	79,968 +35,236	+79%	+$20.1K	﹤0.01%	5084
2024 Q4	$25.2K	Buy	44,732 +5,040	+13%	+$2.98K	﹤0.01%	5241
2024 Q3	$23.8K	Buy	39,692 +28,201	+245%	+$41.8K	﹤0.01%	5157
2024 Q2	$31K	Sell	11,491 -108,017	-90%	-$407K	﹤0.01%	4846
2024 Q1	$613K	Buy	+119,508	New	+$387K	﹤0.01%	3428
2023 Q4	–	Sell	-18,350	Closed	-$12.2K	–	5744
2023 Q3	$12.2K	Buy	+18,350	New	+$18.6K	﹤0.01%	4502

Other funds holding ELEV

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Citigroup's ELEV Position: Q3 2025 in Review

Citigroup sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 13,442 shares — an estimated $4.93K sold.

Citigroup first reported a position in ELEV in Q3 2023 and held it in 7 quarters. The position peaked at $613K in Q1 2024. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.

Citigroup reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
Citigroup sold 13,442 Elevation Oncology shares in Q3 2025, an estimated $4.93K.
Citigroup first reported a position in Elevation Oncology in Q3 2023 and held it in 7 quarters.
Citigroup's Elevation Oncology position peaked at $613K in Q1 2024.
1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.

Based on Citigroup's 13F filing for Q3 2025, filed 10 Nov 2025.